<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Pinnacle Biologics 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=15043></link><description><![CDATA[Pinnacle Biologics 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Sat, 16 May 2026 15:28:38 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><language>ko-KR</language><item><title><![CDATA[Pinnacle Biologics Acquires PHOTOFRIN(R) and PHOTOBARR(R), Novel Photodynamic Therapy for Treating Various Types of Cancer]]></title><link>https://www.newswire.co.kr/newsRead.php?no=535446</link><description><![CDATA[BANNOCKBURN, IL--(Korea Newswire)--Pinnacle Biologics, Inc., a privately held specialty bio-pharmaceutical company announced today the global acquisition of PHOTOFRIN® and PHOTOBARR® from Axcan Pharma, Inc. Financial terms were not disclosed.  A novel therapeutic technique, PHOTOFRIN® is approved for the treatment of non-small cell lung cancer (NSCLC) and esophageal cancer. The p...]]></description><pubDate>Wed, 30 Mar 2011 19:44:51 +0900</pubDate></item><item><title><![CDATA[Pinnacle Biologics, 다양한 암을 치료하는 새로운 광역동 요법인 PHOTOFRIN(R) 및 PHOTOBARR(R) 인수]]></title><link>https://www.newswire.co.kr/newsRead.php?no=535445</link><description><![CDATA[배녹번 일리노이주--(뉴스와이어)--바이오의약품 전문 비상장 기업인 Pinnacle Biologics, Inc.는 Axcan Pharma, Inc.로부터 PHOTOFRIN® 및 PHOTOBARR® 을 전부 인수한다고 오늘 발표했다. 금전적 조건은 공개되지 않았다.  신약 요법 기술인 PHOTOFRIN®은 비소형세포 폐암(NSCLC) 및 식도암 치료 용도로 승인되었다. 이 제품은 미국, 캐나다 및 여러 주요 유럽 국가와 일본 그리고 여러 남미 및 동남아시아 ...]]></description><pubDate>Wed, 30 Mar 2011 19:41:51 +0900</pubDate></item></channel></rss>